Abstract
Aim: The aim of the paper is to study the prevalence of Dravet Syndrome (DS) in the Polish population and indicate different factors other than seizures reducing the quality of life in such patients. Method: A survey was conducted among caregivers of patients with DS by the members of the Polish support group of the Association for People with Severe Refractory Epilepsy DRAVET.PL. It included their experience of the diagnosis, seizures, and treatment-related adverse effects. The caregivers also completed the PedsQL survey, which showed the most important problems. The survey received 55 responses from caregivers of patients with DS (aged 2–25 years). Results: Prior to the diagnosis of DS, 85% of patients presented with status epilepticus lasting more than 30 min, and the frequency of seizures (mostly tonic-clonic or hemiconvulsions) ranged from 2 per week to hundreds per day. After the diagnosis of DS, patients remained on polytherapy (drugs recommended in DS). Before diagnosis, some of them had been on sodium channel blockers. Most patients experienced many adverse effects, including aggression and loss of appetite. The frequency of adverse effects was related to the number of drugs used in this therapy, which had an impact on the results of the PedsQL form, particularly in terms of the physical and social spheres. Intensive care unit stays due to severe status epilepticus also had an influence on the results of the PedsQL form. Conclusions: Families must be counseled on non-pharmacologic strategies to reduce seizure risk, including avoidance of triggers that commonly induce seizures (including hyperthermia, flashing lights and patterns, sleep abnormalities). In addition to addressing seizures, holistic care for a patient with Dravet syndrome must involve a multidisciplinary team that includes specialists in physical, occupational and speech therapy, neuropsychology, social work.
Highlights
Dravet Syndrome (DS, EIEE6, MIM607208), known as severe myoclonic epilepsy of infancy (SMEI), was described for the first time by French psychiatrist and epileptologist Charlotte Dravet in 1978
According to the International League Against Epilepsy (ILAE), DS belongs to the group of developmental and epileptic encephalopathies (DEE) with the prevalence of 1:2000 children and is responsible for 10% of DEE
Decreased function of Nav1.1 sodium channels in GABAergic inhibitory interneurons leads to regression of psychomotor development, refractory epilepsy, and numerous comorbidities, which may reduce the quality of life of patients and their families [4]
Summary
Dravet Syndrome (DS, EIEE6, MIM607208), known as severe myoclonic epilepsy of infancy (SMEI), was described for the first time by French psychiatrist and epileptologist Charlotte Dravet in 1978. The gene locus for DS is located on chromosome 2q24.3 [1]. 90% of patients carry a heterozygous de novo mutation. About 75–85% of individuals affected by DS have loss-of-function mutations in the SCN1A gene encoding the sodium channel alpha subunit [2]. In SCN1A mutation negative patients with clinical similarity to DS, different genetic background is found, the following gene mutations: PCDH19, CHD2, STXBP1, HCN1, GABRG2, GABRA1, and SCN1B [3]. Decreased function of Nav1.1 sodium channels in GABAergic inhibitory interneurons leads to regression of psychomotor development, refractory epilepsy, and numerous comorbidities (motor, behavioral and cognitive impairment), which may reduce the quality of life of patients and their families [4]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.